Methods for treating cancer using prostate specific antigen and tumor endothelial marker peptides
AssigneeThe Board of Trustees of the University of Illinois
InventorsSupriya M. Perambakam, David J. Peace
Life of this patent
Estimating the term…
Abstract
The present invention is directed to prostate specific antigen (PSA) and tumor endothelial marker 8 (TEM8) peptide compositions and methods for treating cancer with the compositions.
Claims21
-40. (canceled)
A method of treating prostate cancer comprising administering to a patient in need thereof an effective amount of peptides comprising:
- (i) prostate specific antigen (PSA) peptide PSA 146-154 (SEQ ID NO:
- 3), and
- (ii) PSA peptide PSA 154-173 (SEQ ID NO:
- 1), PSA peptide PSA 210-230 (SEQ ID NO:
- 2), tumor endothelial marker 8 (TEM8) peptide TEM8 298-306 (SEQ ID NO:
- 18), or combinations of two or more of the three peptides with the peptide of (i).
A composition comprising:
- (i) a pharmaceutically acceptable carrier,
- (ii) prostate specific antigen (PSA) peptide PSA 146-154 (SEQ ID NO:
- 3), and
- (iii) PSA peptide PSA 154-173 (SEQ ID NO:
- 1), PSA peptide PSA 210-230 (SEQ ID NO:
- 2), tumor endothelial marker 8 (TEM8) peptide TEM8 298-306, or combinations thereof.
A kit comprising a composition, instructions for administration of the composition and a device for administering the composition to a patient, wherein the composition comprises:
- (i) a pharmaceutically acceptable carrier,
- (ii) prostate specific antigen (PSA) peptide PSA 146-154 (SEQ ID NO:
- 3), and
- (iii) PSA peptide PSA 154-173 (SEQ ID NO:
- 1), PSA peptide PSA 210-230 (SEQ ID NO:
- 2), tumor endothelial marker 8 (TEM8) peptide TEM8 298-306, or combinations thereof.
A method of identifying a patient that is a candidate for prostate cancer therapy comprising the step of:
- measuring expression level in a sample from a test individual of one or more genes identified in Table 1 relative to a reference expression level,
- wherein an increase or a decrease in expression of the one or more genes identified in Table 1 relative to the reference expression level is determinative for identifying whether the patient is a candidate for prostate cancer therapy.
A method of rendering an individual a candidate for prostate cancer therapy comprising the steps of:
- (a) modulating expression of at least one gene listed in Table 1 to a degree that renders the individual a candidate for prostate cancer therapy;
- and
- (b) administering a therapeutically effective amount of:
- (i) prostate specific antigen (PSA) peptide PSA 146-154 (SEQ ID NO:
- 3), and
- (ii) PSA peptide PSA 154-173 (SEQ ID NO:
- 1), PSA peptide PSA 210-230 (SEQ ID NO:
- 2), tumor endothelial marker 8 (TEM8) peptide TEM8 298-306 (SEQ ID NO:
- 18), or combinations of two or more of the three peptides.
Dependencies are inferred from the claim text.